113 related articles for article (PubMed ID: 7482407)
1. Soluble thrombomodulin purified from human urine exhibits a potent anticoagulant effect in vitro and in vivo.
Takahashi Y; Hosaka Y; Niina H; Nagasawa K; Naotsuka M; Sakai K; Uemura A
Thromb Haemost; 1995 May; 73(5):805-11. PubMed ID: 7482407
[TBL] [Abstract][Full Text] [Related]
2. Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: comparison with low molecular weight heparin.
Takahashi Y; Hosaka Y; Imada K; Adachi T; Niina H; Watanabe M; Mochizuki H
Thromb Haemost; 1997 Apr; 77(4):789-95. PubMed ID: 9134660
[TBL] [Abstract][Full Text] [Related]
3. Amplified anticoagulant activity of tissue factor-targeted thrombomodulin: in-vivo validation of a tissue factor-neutralizing antibody fused to soluble thrombomodulin.
Wang YX; Wu C; Vincelette J; Martin-McNulty B; Alexander S; Larsen B; Light DR; McLean K
Thromb Haemost; 2006 Sep; 96(3):317-24. PubMed ID: 16953273
[TBL] [Abstract][Full Text] [Related]
4. Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III.
Aoki Y; Ohishi R; Takei R; Matsuzaki O; Mohri M; Saitoh K; Gomi K; Sugihara T; Kiyota T; Yamamoto S
Thromb Haemost; 1994 Apr; 71(4):452-5. PubMed ID: 8052962
[TBL] [Abstract][Full Text] [Related]
5. [Thrombomodulin].
Ohmori Y; Takahashi Y
Nihon Yakurigaku Zasshi; 2000 Nov; 116(5):283-9. PubMed ID: 11215378
[TBL] [Abstract][Full Text] [Related]
6. Increased anticoagulant activity of recombinant thrombomodulin modified with glycosaminoglycan.
Edano T; Inoue K; Yoshizaki H; Yamamoto S; Komine N; Tabunoki H; Sawada H; Koshi T; Murakami A; Wada Y; Ohkuchi M
Biol Pharm Bull; 1998 Apr; 21(4):375-81. PubMed ID: 9586576
[TBL] [Abstract][Full Text] [Related]
7. The glycosaminoglycan of recombinant human soluble thrombomodulin affects antithrombotic activity in a rat model of tissue factor-induced disseminated intravascular coagulation.
Nawa K; Itani T; Ono M; Sakano K; Marumoto Y; Iwamoto M
Thromb Haemost; 1992 Mar; 67(3):366-70. PubMed ID: 1322570
[TBL] [Abstract][Full Text] [Related]
8. Soluble thrombomodulin is antithrombotic in the presence of neutralising antibodies to protein C and reduces circulating activated protein C levels in primates.
Tanaka KA; Fernández JA; Marzec UM; Kelly AB; Mohri M; Griffin JH; Hanson SR; Gruber A
Br J Haematol; 2006 Jan; 132(2):197-203. PubMed ID: 16398653
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats.
Uchiba M; Okajima K; Murakami K; Nawa K; Okabe H; Takatsuki K
Thromb Haemost; 1995 Nov; 74(5):1265-70. PubMed ID: 8607107
[TBL] [Abstract][Full Text] [Related]
10. [Antithrombotic effect of recombinant human thrombomodulin on experimentally induced thrombosis in rats].
Shinmyozu K; Maruyama I
Rinsho Ketsueki; 1991 May; 32(5):497-503. PubMed ID: 1651429
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic effects of recombinant human soluble thrombomodulin in a rat model of vascular shunt thrombosis.
Ono M; Nawa K; Marumoto Y
Thromb Haemost; 1994 Sep; 72(3):421-5. PubMed ID: 7855794
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment with activated protein C or active human urinary thrombomodulin attenuates the production of cytokine-induced neutrophil chemoattractant following ischemia/reperfusion in rat liver.
Yamaguchi Y; Hisama N; Okajima K; Uchiba M; Murakami K; Takahashi Y; Yamada S; Mori K; Ogawa M
Hepatology; 1997 May; 25(5):1136-40. PubMed ID: 9141430
[TBL] [Abstract][Full Text] [Related]
13. In vitro anticoagulant properties of a minimum functional fragment of human thrombomodulin and in vivo demonstration of its benefit as an anticoagulant in extracorporeal circulation using a monkey model.
Suzuki M; Mohri M; Yamamoto S
Thromb Haemost; 1998 Feb; 79(2):417-22. PubMed ID: 9493601
[TBL] [Abstract][Full Text] [Related]
14. Species specificity of the anticoagulant activity of human urinary soluble thrombomodulin.
Takahashi Y; Hosaka Y; Imada K; Adachi T; Niina H; Mochizuki H
Thromb Res; 1998 Feb; 89(4):187-97. PubMed ID: 9651146
[TBL] [Abstract][Full Text] [Related]
15. In vivo behavior of detergent-solubilized purified rabbit thrombomodulin on intravenous injection into rabbits.
Ehrlich HJ; Esmon NL; Bang NU
J Lab Clin Med; 1990 Feb; 115(2):182-9. PubMed ID: 2153745
[TBL] [Abstract][Full Text] [Related]
16. Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats.
Yamazaki M; Asakura H; Aoshima K; Saito M; Jokaji H; Uotani C; Kumabashiri I; Morishita E; Ikeda T; Matsuda T
Thromb Haemost; 1994 Sep; 72(3):392-6. PubMed ID: 7855790
[TBL] [Abstract][Full Text] [Related]
17. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma procarboxypeptidase B.
Hosaka Y; Takahashi Y; Ishii H
Thromb Haemost; 1998 Feb; 79(2):371-7. PubMed ID: 9493593
[TBL] [Abstract][Full Text] [Related]
18. The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation--a comparison with other anticoagulants.
Mohri M; Sugimoto E; Sata M; Asano T
Thromb Haemost; 1999 Dec; 82(6):1687-93. PubMed ID: 10613656
[TBL] [Abstract][Full Text] [Related]
19. 6,7-Dihydroxy-3-phenylcoumarin inhibits thromboplastin induced disseminated intravascular coagulation.
Tunali T; Yarat A; Bulut M; Emekli N
Br J Haematol; 2004 Jul; 126(2):226-30. PubMed ID: 15238144
[TBL] [Abstract][Full Text] [Related]
20. Effect of human urinary thrombomodulin on endotoxin-induced intravascular coagulation and pulmonary vascular injury in rats.
Uchiba M; Okajima K; Murakami K; Johno M; Okabe H; Takatsuki K
Am J Hematol; 1997 Feb; 54(2):118-23. PubMed ID: 9034285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
